On March 9, 2021 MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, reported that it will publish its results for the financial year 2020 on March 15, 2021 at 10:00 pm CET (5:00 pm EDT) (Press release, MorphoSys, MAR 9, 2021, View Source [SID1234576318]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
MorphoSys’ Management team will host a conference call and webcast on March 16, 2021 at 2:00 pm CET (9:00 am EDT) to present results for the financial year 2020 and provide an outlook for 2021.
The conference call will start with a presentation by the Management team followed by a Q&A session. Presenters will be:
– Jean-Paul Kress, M.D., Chief Executive Officer
– Sung Lee, Chief Financial Officer
– Roland Wandeler, Ph.D., Chief Operating Officer
– Malte Peters, M.D., Chief Research & Development Officer